Vildagliptin 50 Mg

VILDAGLIPTIN 50 MG tablet is indicated for the treatment of type 2 diabetes mellitus in adults as monotherapy or in combination with insulin.

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Store in original package; protect from moisture

Neurologic: Dizziness, Headache Respiratory: Nasopharyngitis Side effects may include tremor, headache, nausea, hypoglycemia, fatigue, constipation, asthenia, edema, and arthralgia

Talk to your doctor, pharmacist or nurse before taking Vidagliptin: • if you have type 1 diabetes (i.e. your body does not produce insulin) or if you have a condition called diabetic ketoacidosis. • if you are taking an anti-diabetic medicine known as a sulphonylurea (your doctor may want to reduce your dose of the sulphonylurea when you take it together with Jalra in order to avoid low blood glucose [hypoglycaemia]). • if you have moderate or severe kidney disease (you will need to take a lower dose of Jalra). • if you are on dialysis. • if you have liver disease. • if you suffer from heart failure. • if you have or have had a disease of the pancreas. If you have previously taken vildagliptin but had to stop taking it because of liver disease, you should not take this medicine. Diabetic skin lesions are a common complication of diabetes. You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse. You are also advised to pay particular attention to new onset of blisters or ulcers while taking Jalra. Should these occur, you should promptly consult your doctor.

Product Information: Galvus oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2016. Product Information: Xiliarx oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2015. Product Information: Jalra oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2015.

Vildagliptin is a complete dipeptidyl peptidase-4 inhibitor, such inhibition results in increased postprandial and fasting endogenous levels of the incretins glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide. Increased levels of these hormones improves glucose-dependent insulin secretion from pancreatic beta cells. It works by making the pancreas produce more insulin and less glucagon. This helps to control the blood sugar level. This medicine has been shown to reduce blood sugar, which may help to prevent complications from your diabetes. Even though you are now starting a medicine for your diabetes, it is important that you continue to follow the diet and/or exercise which has been recommended for you.

Anti Diabetic